{"id":"68ga-htk03149","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"featherless-qwen","explanation":"This drug is designed to bind to specific targets in tumors, allowing for detailed imaging through positron emission tomography (PET). The gallium-68 isotope emits positrons, which can be detected to create high-resolution images of tumor locations and characteristics.","oneSentence":"68Ga-HTK03149 is a radiolabeled compound used for imaging purposes, particularly in oncology.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T02:27:29.860Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Imaging of neuroendocrine tumors and other cancers expressing somatostatin receptors"}]},"trialDetails":[{"nctId":"NCT05570994","phase":"PHASE1, PHASE2","title":"177Lu-HTK03170 in mCRPC With PSMA Positive Disease","status":"ENROLLING_BY_INVITATION","sponsor":"British Columbia Cancer Agency","startDate":"2024-01-01","conditions":"Metastatic Castration-resistant Prostate Cancer, Prostate Cancer Metastatic, Castrate Resistant Prostate Cancer","enrollment":50},{"nctId":"NCT04495959","phase":"","title":"Dynamic Whole Body PET/ MRI","status":"WITHDRAWN","sponsor":"British Columbia Cancer Agency","startDate":"2025-08-01","conditions":"Prostatic Cancer","enrollment":""},{"nctId":"NCT04831307","phase":"NA","title":"68Ga-HTK03149 for Use as a Diagnostic Radiopharmaceutical","status":"UNKNOWN","sponsor":"British Columbia Cancer Agency","startDate":"2021-08-30","conditions":"Prostate Cancer, Prostatic Neoplasm, Prostatic Disease","enrollment":10}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"68Ga-HTK03149","genericName":"68Ga-HTK03149","companyName":"British Columbia Cancer Agency","companyId":"british-columbia-cancer-agency","modality":"Small molecule","firstApprovalDate":"","aiSummary":"68Ga-HTK03149 is a radiolabeled compound used for imaging purposes, particularly in oncology. Used for Imaging of neuroendocrine tumors and other cancers expressing somatostatin receptors.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}